Anastrozole after tamoxifen improves cancer outcomes

Article

Women who have taken tamoxifen for 2 years as adjuvant chemotherapy for breast cancer may receive greater clinical benefit if they switch to anastrozole rather than continuing with tamoxifen, researchers report in the July 1 issue of the Journal of Clinical Oncology.

Women who have taken tamoxifen for 2 years as adjuvant chemotherapy for breast cancer may receive greater clinical benefit if they switch to anastrozole rather than continuing with tamoxifen, researchers report in the July 1 issue of the Journal of Clinical Oncology.

Manfred Kaufmann, MD, from the J.W. Goethe-University of Frankfurt in Germany, and others randomly assigned 979 patients receiving tamoxifen for 2 years to anastrozole at 1 mg/day for an additional 3 years or to a full 5-year course of tamoxifen to compare the disease-free survival rates. Overall survival and safety were also measured.

The investigators found that switching to anastrozole reduced the risk of disease recurrence (hazard ratio, 0.66) and improved overall survival (HR, 0.53). More side effects were apparent in the continued tamoxifen group, largely due to endometrial events.

The study was supported by a grant from AstraZeneca and some of the authors report receiving consulting fees, honoraria or grants from AstraZeneca, Pfizer and/or Novartis.

Kaufmann M, Jonat W, Hilfrich J, et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 Study. J Clin Oncol. 2007;25:2664-2670.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Ousseny Zerbo, PhD, highlights benefits of influenza vaccination during pregnancy | Image Credit: divisionofresearch.kaiserpermanente.org.
Michael Ussher, PhD, highlights the benefits of vaping over smoking in pregnancy | Image Credit: sgul.ac.uk.
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Related Content
© 2025 MJH Life Sciences

All rights reserved.